Patients
Keyline's programs are investigational. They are not approved, and today the only way to receive one is in a clinical trial.
Each study has its own rules for who can join. Your doctor can help you decide if a trial is right for you.
Sample trial for this demoOncology · Phase 1
Adults with recurrent or metastatic head and neck squamous cell carcinoma after standard therapy. Five sites in the United States.
On a real site, each trial links to its record on ClinicalTrials.gov, the US registry of clinical studies.
Expanded access (sometimes called compassionate use) lets a patient with a serious disease get an investigational therapy outside a clinical trial. US law asks companies to publish how they handle these requests.
Keyline does not offer expanded access to KL-101 at this time. The Phase 1 study is still finding a safe dose, and we do not yet know enough to give it outside a study. We will review this policy as the program moves forward and post any change here.
A licensed physician can send a request to clinicaltrials@keyline.xiobocreative.com. Please include the disease, past treatments and why a clinical trial is not an option.
We confirm each request within 5 business days. We review every request in the same way, with our medical team.
FDA: about expanded access →This page does not give medical advice. Talk to your doctor about your care. Last reviewed October 2026.
